Summary & Overview
HCPCS S0156: Exemestane, 25 mg
HCPCS Level II code S0156 denotes Exemestane, 25 mg, an oral aromatase inhibitor used in hormone receptor–positive breast cancer care. As a drug-specific HCPCS Level II code, S0156 is used to report the provision or supply of the 25 mg tablet strength of exemestane for outpatient dispensing. Nationally, accurate coding of oral oncology agents influences drug coverage determination, patient cost-sharing, and pharmacy reimbursement pathways.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical role of exemestane in endocrine therapy, typical sites of service where S0156 is billed (outpatient pharmacy and clinic dispensing), and the billing context for a drug-specific HCPCS Level II entry. The publication summarizes common modifiers and administrative considerations where available and highlights the practical implications of using a HCPCS Level II drug code versus other drug reporting mechanisms.
This report provides national-level clarity on coding practice, payer coverage considerations, and the administrative elements relevant to billing S0156 for outpatient medication supply. Data not available in the input are identified where applicable.
Billing Code Overview
HCPCS Level II code S0156 represents Exemestane, 25 mg, an oral aromatase inhibitor used in hormone receptor–positive breast cancer therapy. The service type is oral anti-neoplastic (hormonal) medication administration / supply, documenting the specific drug strength provided.
Typical site of service for S0156 is outpatient pharmacy or clinic-based medication dispensing where oral oncologic medications are supplied to patients for take-home use.
Clinical & Coding Specifications
Clinical Context
A typical patient is a postmenopausal woman with hormone receptor–positive early-stage or metastatic breast cancer receiving oral aromatase inhibitor therapy. The medication administered under HCPCS Level II code S0156 is Exemestane, 25 mg, prescribed for daily oral use to reduce estrogen synthesis. Clinical workflow begins with an oncology or gynecologic oncology consultation where the diagnosis and endocrine therapy plan are documented. Baseline assessments include menopausal status, bone mineral density, liver function tests, and a medication reconciliation for interacting drugs. The prescription is dispensed by an outpatient infusion pharmacy or specialty pharmacy; coverage verification and prior authorization may be completed by clinical staff. Follow-up visits occur every 3 months initially to assess tolerance, adherence, and adverse effects (arthralgia, hot flashes, osteoporosis risk) with periodic labs and imaging per oncologist discretion. Supportive care (calcium/vitamin D, bisphosphonates or denosumab when indicated) is coordinated with primary care or endocrinology. Billing for the medication uses S0156 and may include appropriate payer-specific modifiers when reporting dispensing, reimbursement adjustments, or split/shared services.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |